Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
Type 2 myocardial infarction (MI) is common and associated with poor clinical outcomes, with
as many as one in ten experiencing recurrent MI within one year, and only one in three alive
at five years. Recent prospective data demonstrates two-thirds of patients with type 2 MI
have underlying coronary artery disease and one-third have left ventricular systolic
impairment. Importantly, this is previously unrecognised in over half of all patients,
suggesting there may be opportunities to identify and treat these underlying conditions to
modify clinical outcomes. The investigators will undertake a pilot randomised controlled
trial in which patients will be randomised to standard care or a complex intervention
involving detailed cardiology assessment for the likelihood of coronary disease or left
ventricular impairment, followed by targeted investigation and treatment where underlying
disease is identified. This study will inform the design and delivery of a prospective
multi-centre randomised controlled trial powered for clinical outcomes.